The APHINITY trial demonstrated 3-year invasive disease-free survival (DFS) of 92% among node-positive early-stage HER2+ breast cancer patients treated with trastuzumab (H) and pertuzumab (P) plus adjuvant chemotherapy1. The gene discussed is ERBB2; the disease is breast carcinoma.